Onkologie. 2017:11(3):134-137

Chronic myeloid leukaemia – second line therapy bosutinib: 4-year follow up

Lucia Vráblová, Edgar Faber
Hemato-onkologická klinika, Fakultní nemocnice Olomouc

The dual SRC/ABL1 tyrosine kinase inhibitor bosutinib is indicated for the adult patients with Ph-positive chronic myeloid leukaemia

(CML) resistant/intolerant to prior therapy. The commentary of the study written by Tim Brümmendorf et al. published in the

British Journal of Haematology in 2016 is provided. The study is focused on the factors associated with the long-term efficacy and

safety of bosutinib given in adults with imatinib resistant or intolarent chronic phase of the disease.

Keywords: chronic myeloid leukaemia, bosutinib, tyrosine kinase inhibitor, second line therapy

Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vráblová L, Faber E. Chronic myeloid leukaemia – second line therapy bosutinib: 4-year follow up. Onkologie. 2017;11(3):134-137.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brummendorf TH, et al. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology 2016; 172: 97-110. Go to original source... Go to PubMed...
    2. Gambacorti-Passerini C, et al. Bosutinibefficacy and safery in chronic phase of chronic myeloid leukaemia after imatinib resistance or intolerance: minimum 24 months follow-up.Americanjournalof Hematology 2014; 89: 732-742. Go to original source...
    3. Khoury HJ, Bosutinib is aktive in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy silure. Blood 2012; 119: 3403-3412. Go to original source... Go to PubMed...
    4. Kantarijan H, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551. Go to original source... Go to PubMed...
    5. Hochhaus A, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200-1206. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.